Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher, Cedars-Sinai to Collaborate on Protein Mass Spec Workflows for Clinical Research

NEW YORK – Thermo Fisher Scientific said today that it is collaborating with physicians and scientists at Cedars-Sinai, a nonprofit academic healthcare organization based in Los Angeles, to develop liquid chromatography mass spectrometry workflows for clinical research.

"New LC-MS-based methods will be developed to deliver high quality and confident results regardless of user expertise and experience for laboratories seeking to identify novel biomarkers and monitor biotherapeutics, ultimately helping clinical research teams track and improve outcomes," said Bradley Hart, senior director of clinical marketing, chromatography, and mass spectrometry at Thermo Fisher, in a statement.

"The goal is to develop advanced LC-MS-based workflows for the untargeted screening and targeted quantitation of protein-based biomarkers for critical disease states, which hold the potential to benefit not only our own patients, but also the wider clinical community," said Jennifer Van Eyk, principal investigator for research and director of the Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences at Cedars-Sinai, in a statement.

Specifically, the partners plan to develop data acquisition strategies for global plasma protein profiling and peptide selective reaction monitoring (SRM) assays for the analysis of plasma with our without enrichment; to optimize quantitative intact protein analysis methods for plasma using Thermo Scientific Q Exactive Orbitrap mass spec technology; and to assess targeted protein workflows with Thermo Fisher's new triple quadrupole mass spectrometers for large quantitation assays within a CLIA environment.